OakChart

Corvus Pharmaceuticals Inc

CRVSHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

11.47+0.10 (0.88%)
2026-11-12 05:49 CET
Market cap
967.53 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-64.31 USD m
Free cash flow, TTM
-47.94 USD m
EPS diluted, TTM
-0.71
P/E
-
Compare

Price

CRVS against its 20, 50 and 200-day averages
2050200miss
10.0012.0014.0016.002.2M4.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRVSclose 11.4720-day 10.3450-day 11.33200-day 14.0911.47

57.4% under the 52-week high of 26.95 on 23 Jan 2026. 52-week low 6.39 on 12 Jan 2026. Last 15 sessions, 23.0% high to low

Volume 0.80× normal · the line is the 50-bar volume average

Profile

CRVS
52-week range, 25% of the way up
6.3926.95

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

IndexRUT
Employees37
IPOMar 23, 2016
Beta1.51
ATR, 14d0.69
Rel volume0.80
Short float27.33%
Insider own22.97%
Inst own65.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap967.54M
Enterprise Value765.22M
Income-64.31M
Sales0.00M
Book/sh2.47
Cash/sh2.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees37
IPOMar 23, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.64
P/C4.77
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.38
Current Ratio13.38
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.71
EPS next Y-1.05
EPS next Q-0.23
EPS this Y-324.66%
EPS next Y-29.73%
EPS next 5Y-
EPS past 3/5Y15.40% -21.44%
Sales past 3/5Y- -
EPS Y/Y TTM-272.40%
Sales Y/Y TTM-
EPS Q/Q-79.45%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.-14.35% -

Ownership

Insider Own22.97%
Insider Trans0.15%
Inst Own65.60%
Inst Trans1.03%
ROA-42.26%
ROE-45.92%
ROIC-30.85%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.92%
SMA501.21%
SMA200-18.62%
Trades-

Technical

Shs Outstand84.32M
Shs Float64.97M
Short Float27.33%
Short Ratio17.20
Short Interest17.76M
52W High26.95 -57.44%
52W Low6.39 79.50%
Volatility8.83% 6.46%
ATR (14)0.69
RSI (14)58.15
Beta1.51
Rel Volume0.80
Avg Volume1.03M
Volume822,187

Performance

Perf Week8.51%
Perf Month21.89%
Perf Quarter-24.24%
Perf Half Y-27.59%
Perf YTD48.96%
Perf Year40.39%
Perf 3Y725.18%
Perf 5Y158.92%
Perf 10Y-28.13%
Recom1.14
Target Price31.50
Prev Close11.37
Price11.47
Change %0.88%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Apr 17, 2026InitiatedGGoldmanBuy$40+248.7%
Oct 13, 2025InitiatedBBarclaysOverweight$16+39.5%
Jan 02, 2025InitiatedHH.C. WainwrightBuy$11-4.1%
Aug 18, 2023InitiatedOOppenheimerOutperform$7-39.0%
Dec 01, 2021ResumedJJefferiesBuy$8-30.3%
May 27, 2021InitiatedCCantor FitzgeraldOverweight$10-12.8%
Feb 10, 2021DowngradeMMizuhoBuy → Neutral$7 → $4-65.1%
Sep 12, 2019InitiatedMMizuhoBuy
May 29, 2019InitiatedRROTH CapitalBuy$6-47.7%
Aug 24, 2017UpgradeCCredit SuisseUnderperform → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
ACRSAclaris Therapeutics Inc688.38M
ALMSAlumis Inc883.74M
KYMRKymera Therapeutics Inc11.51B
EVMNEvommune Inc312.84M
INCYIncyte Corp24.92B
ARQTArcutis Biotherapeutics Inc3.59B
ORKAOruka Therapeutics Inc7.27B
RIGLRigel Pharmaceuticals838.31M
UPBUpstream Bio Inc175.27M
ABBVAbbvie Inc521.41B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Moore David ScottDirectorJun 11 '26Buy11.5321,700250,23621,700Jun 15 05:12 PM
MILLER RICHARD A MDPresident and CEOMay 18 '26Buy12.046,93283,4531,195,035May 20 04:12 PM
Thompson Peter A.DirectorJan 28 '26Option Exercise5.33210,0001,119,374210,000Jan 30 06:39 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VHTVanguard Health Care ETFAUM: 21.51B
IDNAiShares Genomics Immunology and Healthcare ETFAUM: 354.14M

News

latest 14 of 200
  • Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire) +7.69%
  • Corvus Misses By A Penny As The Soquelitinib Pipeline Widens But Key Milestones Slip Further Into 2027 (Earnings Whispers) -7.95% +8.32%
  • Corvus: Q3 Earnings Snapshot (Associated Press)
  • Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68?? American Society for Hematology Annual Meeting & Exposition (GlobeNewswire) +7.53%
  • Corvus Faces Execution Test As Trial Launches, Spending Ramp And PTCL Timing Converge (Earnings Whispers)
  • Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa (GlobeNewswire) -5.12%
  • Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
  • Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... (GuruFocus.com)
  • Corvus: Q2 Earnings Snapshot (Associated Press)
  • Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.220-0.192-0.2200.000.007
2026Q22026-08-06-0.190-0.159-0.1940.000.008
2026Q12026-05-07-0.150-0.142-0.1520.000.007
2025Q42026-03-12-0.150-0.129-0.1490.000.007
2025Q32025-11-04-0.120-0.127-0.1230.000.007
2025Q22025-08-07-0.100-0.133-0.1030.000.006
2025Q12025-05-08-0.130-0.120-0.1320.000.006
2024Q42025-03-25-0.180-0.117-0.1770.000.006
2024Q32024-11-12-0.600-0.110-0.6030.000.004
2024Q22024-08-06-0.070-0.115-0.0710.000.004
2024Q12024-05-06-0.120-0.135-0.1160.000.002
2023Q42024-03-19-0.140-0.120-0.1360.000.004
2023Q32023-11-07-0.120-0.123-0.1230.000.004
2023Q22023-08-08-0.140-0.140-0.1370.000.004
2023Q12023-05-08-0.170-0.157-0.1690.000.003
2022Q42023-03-28-0.210-0.207-0.2110.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.590-1.537-1.5900.000.00
2020FY-0.200-1.458-0.2030.000.00
2021FY-1.030-0.963-1.0330.000.00
2022FY-0.890-0.820-0.8870.000.00
2023FY-0.560-0.548-0.5630.000.00
2024FY-1.020-0.922-1.0210.000.00
2025FY-0.190-0.245-0.1900.000.00
2026FY--0.807--0.00
2027FY--1.047--1.26
2028FY--1.153--26.92
2029FY--0.828--73.26
2030FY--0.220--149.29

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-065000.000.000.00
2026Q4S2026-11-055000.000.000.00
2026Q4S2026-10-295000.000.000.00
2026Q4S2026-08-106000.000.000.00
2026Q4S2026-08-075000.000.000.00
2026Q4S2026-07-285000.000.000.00
2026Q4S2026-06-214000.000.000.00
2026Q4S2026-05-085000.000.000.00
2026Q4S2026-04-165000.000.000.00
2026Q4S2026-03-134000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4S2025-11-093000.000.000.00
2026Q4S2025-11-083000.000.000.00

Estimate history

EPS, annual-2.72-1.706-1.59-0.203-1.033-0.887-0.563-1.021-0.537-0.715
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.603-0.177-0.132-0.103-0.123-0.149-0.152-0.194-0.22
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.04129.32427.95328.37346.55446.55449.03967.974.69784.319
Period201720182019202020212022202320242025MRQ
Shares, quarterly62.5867.968.16974.51474.68274.69784.0984.12184.319
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.180.100.090.150.370.460.630.740.85
Gross Profit-0.18-0.10-0.09-0.15-0.37-0.46-0.63-0.74-0.85
Selling, General and Administrative Excl. Other67.5742.8727.4623.2632.2038.1743.1348.1148.38
Research and Development54.8633.7219.3916.5324.4729.1131.8337.9838.59
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-67.75-42.97-27.55-23.41-32.56-38.63-43.76-48.85-49.22
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.00-27.1433.380.000.000.00-37.46--
Net Income Before Taxes-64.31-15.28-62.29-27.03-41.31-43.24-6.00-46.67-46.94
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-64.31-15.28-62.29-27.03-41.31-43.24-6.00-46.67-46.94
Net Income From Continuing Operations-64.31-15.28-62.29-27.03-41.31-43.24-6.00-46.67-46.94
Net Income-64.31-15.28-62.29-27.03-41.31-43.24-6.00-46.67-46.94
EPS (Recurring)-0.70-0.78-0.64-0.56-0.89-1.03-1.09-1.59-1.71
EPS (Basic, Before Extraordinaries)-0.71-0.19-1.02-0.56-0.89-1.03-0.20-1.59-1.71
EPS (Diluted)-0.71-0.54-1.02-0.56-0.89-1.03-0.20-1.59-1.71
EBITDA-67.57-42.87-27.46-23.26-32.20-38.17-43.13-48.11-48.38
Non-Operating Income (Expense)3.440.55-1.37-3.62-8.74-4.610.312.182.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.665.333.002.152.694.235.757.357.13
Shares Outstanding84.3274.7067.9049.0446.5546.5528.3727.9529.32
Market Capitalization967.53967.53343.7886.3139.57112.1899.90159.96107.46

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.030.030.030.030.030.020.02
Gross Profit-0.10-0.03-0.03-0.03-0.03-0.03-0.02-0.02
Selling, General and Administrative Excl. Other21.2719.2614.8512.1910.5410.239.908.09
Research and Development17.7815.9611.189.948.457.877.455.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-21.36-19.30-14.88-12.22-10.57-10.26-9.92-8.11
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.00-2.01-25.132.35
Net Income Before Taxes-20.34-17.96-13.69-12.32-10.16-8.0015.19-12.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.34-17.96-13.69-12.32-10.16-8.0015.19-12.11
Net Income From Continuing Operations-20.34-17.96-13.69-12.32-10.16-8.0015.19-12.11
Net Income-20.34-17.96-13.69-12.32-10.16-8.0015.19-12.11
EPS (Recurring)-0.22-0.19-0.15-0.15-0.12-0.12-0.37-0.15
EPS (Basic, Before Extraordinaries)-0.22-0.19-0.15-0.15-0.12-0.100.21-0.18
EPS (Diluted)-0.22-0.19-0.15-0.15-0.12-0.10-0.13-0.18
EBITDA-21.27-19.26-14.85-12.19-10.54-10.23-9.90-8.09
Non-Operating Income (Expense)1.021.341.19-0.100.410.25-0.01-1.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.832.612.651.571.251.261.250.81
Shares Outstanding84.3284.1284.0974.7074.6874.5168.1767.90
Market Capitalization967.531,256.311,228.81575.05549.17308.46216.67343.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments56.7551.9627.1542.3069.4544.2677.98114.6090.06
Short Term Receivables0.370.220.060.630.540.090.330.340.13
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.092.230.740.731.320.991.030.661.05
Total Current Assets58.2154.4127.9643.6671.3145.3479.34115.5991.23
Net Property, Plant & Equipment1.061.331.392.573.642.553.792.182.67
Total Investments and Advances10.9912.5416.1221.8834.2737.230.000.000.00
Other Assets0.850.630.090.130.240.410.510.460.87
Total Assets71.1268.9145.5568.24109.4585.5383.65118.2394.78
Short Term Debt Incl. Current Port. of LT Debt0.400.181.371.231.051.080.880.000.00
Accounts Payable2.492.581.521.981.563.472.452.003.45
Other Current Liabilities6.4932.633.977.557.087.606.905.035.51
Total Current Liabilities9.3835.406.8710.759.6912.1510.227.038.97
Long Term Debt0.530.940.001.372.601.232.310.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.870.97
Total Liabilities9.9136.346.8712.1212.2913.3812.547.909.94
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity61.2032.5738.6856.1297.1672.1571.11110.3484.83
Total Shareholders Equity61.2032.5738.6856.1297.1672.1571.11110.3484.83
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity61.2032.5738.6856.1297.1672.1571.11110.3484.83
Total Liabilities & Stockholders Equity71.1268.9145.5568.24109.4585.5383.65118.2394.78
Book Value Per Share0.820.480.791.212.092.542.543.764.03
Tangible Book Value Per Share0.820.480.791.212.092.542.543.764.03
Full-Time Employees373128292842534955
Price to Book Ratio4.6426.981.950.611.151.402.140.982.31
Return on Assets-21.83-108.85-47.51-46.49-44.35-7.09-46.24-44.07-47.39
Return on Equity-32.60-174.85-57.02-53.90-51.08-8.37-51.44-48.10-51.15
Return on Invested Capital-24.75-185.92-69.87-71.85-43.34-8.17-63.57-42.54-65.61
Quick Ratio6.211.544.074.067.363.737.7616.4510.17
Current Ratio6.211.544.074.067.363.737.7616.4510.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-64.31-15.28-62.29-27.03-41.31-43.24-6.00-46.67-46.94
Depreciation0.180.100.090.150.370.460.630.740.85
Other Funds (Non Cash)12.73-21.2038.436.5412.519.30-31.326.706.53
Funds from Operations-51.40-36.38-23.78-20.34-28.43-33.48-36.69-39.23-39.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.223.58-1.65-3.591.41-3.241.911.90-1.42
Cash from Operating Activities-47.18-32.80-25.42-23.93-27.02-36.72-34.78-37.32-40.99
Capital Expenditures-0.76-0.170.00-0.03-0.27-0.01-0.08-0.03-0.35
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.010.000.020.000.000.00-
Purchase or Sale of Investments-131.65-7.62-27.4915.57-23.0321.5744.843.28-29.84
Purchase of Investments-258.28-91.75-70.12-47.05-66.19-9.36-42.54-138.59-161.86
Sale Or Maturity of Investments126.6384.1342.6362.6243.1630.9287.39141.87132.02
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-132.41-7.80-27.4815.54-23.2821.5644.773.25-30.19
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock191.7436.4349.037.860.0062.161.310.0265.27
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock191.7436.4349.037.860.0062.161.310.0265.27
Proceedsfrom Stock Options225.1535.7440.037.840.0060.941.220.0064.88
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities191.7436.4349.037.860.0062.161.310.0265.27
Net Change in Cash12.15-4.16-3.88-0.54-50.3047.0011.30-34.04-5.91
Free Cash Flow-47.94-32.97-25.42-23.97-27.29-36.72-34.85-37.35-41.34
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments202.95215.23236.7156.7565.6974.41
Short Term Receivables1.291.851.200.370.350.26
Inventories0.000.000.000.000.000.00
Other Current Assets2.113.892.031.090.911.11
Total Current Assets206.34220.97239.9558.2166.9475.78
Net Property, Plant & Equipment1.361.491.031.061.151.26
Total Investments and Advances14.4715.1110.5010.9911.5311.79
Other Assets1.701.711.720.850.850.63
Total Assets223.88239.27253.1971.1280.4789.46
Short Term Debt Incl. Current Port. of LT Debt0.490.450.430.400.380.35
Accounts Payable5.654.054.702.491.973.14
Other Current Liabilities9.289.176.996.495.725.01
Total Current Liabilities15.4213.6712.119.388.078.51
Long Term Debt0.140.270.410.530.630.73
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities15.5613.9512.529.918.719.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity208.32225.33240.6861.2071.7780.23
Total Shareholders Equity208.32225.33240.6861.2071.7780.23
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity208.32225.33240.6861.2071.7780.23
Total Liabilities & Stockholders Equity223.88239.27253.1971.1280.4789.46
Book Value Per Share2.472.682.860.820.961.08
Tangible Book Value Per Share2.472.682.860.820.961.08
Full-Time Employees---37--
Price to Book Ratio4.645.2217.868.016.855.53
Return on Assets-42.26-32.93-28.26-21.83-21.65-58.61
Return on Equity-45.92-35.43-30.46-32.60-35.82-68.67
Return on Invested Capital-9.76-7.96-5.68-19.96-14.03-9.88
Quick Ratio13.3816.1619.816.218.298.91
Current Ratio13.3816.1619.816.218.298.91

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.34-17.96-13.69-12.32-10.16-8.00
Depreciation0.100.030.030.030.030.03
Other Funds (Non Cash)3.983.503.232.021.11-0.70
Funds from Operations-16.27-14.42-10.43-10.28-9.02-8.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.05-0.980.061.08-0.552.89
Cash from Operating Activities-12.21-15.40-10.37-9.19-9.57-5.78
Capital Expenditures-0.07-0.58-0.09-0.030.00-0.11
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.58-5.38-144.7510.90-2.62-20.19
Purchase of Investments-30.38-52.74-161.74-13.42-31.15-39.48
Sale Or Maturity of Investments37.9747.3616.9824.3228.5319.29
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.52-5.96-144.8510.88-2.62-20.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.810.17190.750.020.3635.77
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.810.17190.750.020.3635.77
Proceedsfrom Stock Options0.000.00189.4135.740.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.810.17190.750.020.3635.77
Net Change in Cash-3.89-21.2035.531.71-11.829.69
Free Cash Flow-12.28-15.98-10.46-9.22-9.57-5.89

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.33%17.8M65.0M998.22K
2026-10-1527.73%18.0M64.8M977.03K
2026-09-3027.47%17.8M64.8M1.01M
2026-09-1526.51%17.2M64.8M1.04M
2026-08-3129.35%19.0M64.8M1.09M
2026-08-1429.52%19.1M64.8M1.35M
2026-07-3128.98%18.3M63.2M1.44M
2026-07-1528.60%18.1M63.2M1.59M
2026-06-3029.80%18.8M63.2M1.48M
2026-06-1528.32%17.9M63.2M1.49M
2026-05-2927.42%17.3M63.2M1.46M
2026-05-1529.93%18.9M63.2M1.35M
2026-04-3028.68%18.4M64.1M1.33M
2026-04-1526.44%16.9M64.0M3.34M
2026-03-3126.62%17.0M63.7M3.47M
2026-03-1325.21%16.1M63.7M3.52M
2026-02-2725.20%16.0M63.5M3.52M
2026-02-1323.43%14.9M63.5M3.45M
2026-01-3022.91%14.7M64.1M3.40M
2026-01-1520.04%11.5M57.3M1.30M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.009.6011.900.000.0000.000.000.994-0.0150.000
call2.008.6010.900.0019.3130.000.000.990-0.0160.000
call3.006.0010.500.0017.2870.000.000.987-0.0160.001
call4.006.608.900.0010.4190.000.000.983-0.0160.001
call5.004.108.800.0011.4820.000.000.979-0.0160.001
call6.003.807.900.009.7540.000.000.973-0.0160.001
call7.003.706.900.008.1660.000.000.966-0.0150.001
call8.001.105.902.706.8701.000.000.933-0.0230.002
call9.000.503.601.003.42081.000.000.824-0.0540.005
call10.001.102.001.551.6681,0071.000.765-0.0460.005
call11.000.401.400.801.6462283.000.631-0.0430.007
call12.000.000.500.301.0043510.000.435-0.0460.007
call13.000.004.900.151.21026.000.000.286-0.0420.006
call14.000.000.500.101.54879.001.000.241-0.0490.006
call15.000.001.150.101.83615.001.000.214-0.0540.005
call16.000.001.000.052.09165.000.000.196-0.0590.005
call17.000.001.750.052.20923.000.000.166-0.0560.004
call18.000.002.000.052.4125.000.000.156-0.0580.004
call19.000.001.750.052.5987.000.000.148-0.0610.004
call20.000.004.500.032.7703.000.000.142-0.0630.004
call21.000.002.950.002.9290.000.000.136-0.0650.004
call22.000.000.750.003.0780.000.000.132-0.0670.004
call23.000.001.000.003.1840.000.000.128-0.0670.004
call24.000.001.000.003.3500.000.000.124-0.0700.004
call25.000.002.550.003.6100.000.000.135-0.0790.004
call26.000.002.750.003.5930.000.000.119-0.0720.004
put1.000.000.050.008.1080.000.00-0.006-0.0140.000
put2.000.000.050.005.7010.000.00-0.010-0.0140.000
put3.000.004.300.004.6490.000.00-0.013-0.0160.001
put4.000.002.200.003.6870.000.00-0.017-0.0160.001
put5.000.002.750.002.9820.000.00-0.021-0.0150.001
put6.000.002.750.002.3970.000.00-0.026-0.0150.001
put7.000.004.900.051.89154.000.00-0.034-0.0140.001
put8.000.000.350.101.7031110.00-0.067-0.0220.002
put9.000.000.700.652.02430.000.00-0.176-0.0530.005
put10.000.000.600.151.45452.004.00-0.235-0.0450.005
put11.000.001.450.300.8779.007.00-0.369-0.0410.007
put12.000.501.350.751.47525.003.00-0.565-0.0440.007
put13.000.554.903.604.7061.000.00-0.714-0.0400.006
put14.001.104.903.753.6920.000.00-0.759-0.0470.006
put15.002.704.305.852.5760.000.00-0.786-0.0530.005
put16.002.805.306.502.8620.000.00-0.804-0.0570.005
put17.003.407.900.004.7651.000.00-0.834-0.0540.004
put18.004.007.400.003.5150.000.00-0.828-0.0630.005
put19.006.708.400.003.7300.000.00-0.837-0.0660.004
put20.007.709.400.003.9290.000.00-0.844-0.0680.004
put21.007.3011.900.006.3690.000.00-0.849-0.0700.004
put22.008.3013.000.006.5540.000.00-0.854-0.0720.004
put23.0010.5012.900.005.2610.000.00-0.858-0.0730.004
put24.0011.5013.900.005.4190.000.00-0.862-0.0750.004
put25.0012.5014.900.005.5680.000.00-0.865-0.0760.004
put26.0012.2017.000.007.3330.000.00-0.868-0.0780.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-228-KCurrent report2026-07-21SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-27SCHEDULE 13G/ASEC
2026-04-274Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-04-273Initial statement of beneficial ownership of securities2026-04-23SEC
2026-04-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-238-KCurrent report2026-04-22SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-138-KCurrent report2026-03-13SEC
2026-03-13424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06250.24K100
2026-0583.45K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC8.52%
BlackRock, Inc.8.49%
STATE STREET CORP5.32%
PRICE T ROWE ASSOCIATES INC /MD/4.51%
VANGUARD CAPITAL MANAGEMENT LLC3.92%
ADAMS STREET PARTNERS LLC3.90%
Vivo Capital, LLC3.34%
WELLINGTON MANAGEMENT GROUP LLP3.25%
PERCEPTIVE ADVISORS LLC3.17%
Deep Track Capital, LP2.96%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.49%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.82%
iShares Russell 2000 ETF2.08%
T. Rowe Price New Horizons Fund, Inc.1.15%
VANGUARD EXTENDED MARKET INDEX FUND1.00%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.95%
Fidelity Small Cap Index Fund0.88%
Hood River Small-Cap Growth Fund0.84%
iShares Russell 2000 Growth ETF0.74%
T. Rowe Price Health Sciences Fund, Inc.0.73%

OakChart. CRVS. Cached 15 minutes.